Category Archives: Inherency

Sigray, Inc. v. Carl Zeis X-Ray Microscopy, Inc.—When does “No” Projection Magnification Mean “No”?

Posted on June 10, 2025 by Warren Woessner

In Sigray, Inc, v. Carl Zeis X-Ray [“Zeiss”], appeal 2023-2211 (Fed. Cir., May 23, 2025), the panel reviewed the Board’s decision in an IPR in which Claims 1-6 of Zeiss patent no. 7,400,704 were held not to be unpatentable over … Continue reading →

Posted in Claim Interpretation, Inherency, Uncategorized | Leave a comment

Regeneron v. Mylan, “It Ain’t Necessarily So.”

Posted on April 27, 2025 by Warren Woessner

Regeneron v. Mylan, appeal nos. 2024-2058, 2024-2147 (Fed. Cir., March 5, 2025) is the most recent appeal in a long line of Hatch-Waxman suits filed by Regeneron to block generic versions of its VEGF antagonist (or “trap”) EYLEA®, that is … Continue reading →

Posted in Inherency | Leave a comment

Method of Treatment Efficacy Benchmarks Avoid Inherency Attack

Posted on February 6, 2020 by Warren Woessner

In Galderma Labs. v. Teva Pharm. USA, Inc., Appeal Nos. 2019-2396 and 2020-1213 (Fed. Cir,. January 29, 2020), a Fed. Cir. panel of Judges Moore, O’Malley and Stoll reversed a district court finding that three Galderma patents (US Pat. Nos. … Continue reading →

Posted in Anticipation, Inherency | Tagged , | Leave a comment

Honeywell International, Inc. v. Mexichem Amanco Holdings – Revenge of the Chemist Judges II

Posted on August 3, 2017 by Warren Woessner

Before reading this post, please read my post of July 19, 2017 about Millennium Pharms. v. Sandoz, and you will “get” the title. Judges Lourie and Newman both dissented from refusal of the court to rehear the holding in Schering … Continue reading →

Posted in Inherency | 1 Comment